These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12907538)

  • 21. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
    Najib MM; Stein GE; Goss TF
    Pharmacotherapy; 2000 Apr; 20(4):461-9. PubMed ID: 10772376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
    Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
    J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
    Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
    Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R; Hernández-Oliva G; Cruz-Alcázar J; Amábile-Cuevas CF; Arvis P; Reimnitz P; Bogner JR;
    Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).
    Ferrara AM
    Clin Interv Aging; 2007; 2(2):179-87. PubMed ID: 18044134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
    Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
    Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
    Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
    Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
    Hammerschlag MR; Roblin PM
    Int J Antimicrob Agents; 2000 Jul; 15(2):149-52. PubMed ID: 10854812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
    Wessels F; Anderson AN; Ebrahim O
    S Afr Med J; 1998 Mar; 88(3):251-5. PubMed ID: 9608289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
    Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
    J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
    Höffken G; Barth J; Rubinstein E; Beckmann H;
    Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
    Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
    Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
    Schaper NC; Dryden M; Kujath P; Nathwani D; Arvis P; Reimnitz P; Alder J; Gyssens IC
    Infection; 2013 Feb; 41(1):175-86. PubMed ID: 23180507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
    Chodosh S; DeAbate CA; Haverstock D; Aneiro L; Church D
    Respir Med; 2000 Jan; 94(1):18-27. PubMed ID: 10714475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
    Davis SL; Delgado G; McKinnon PS
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.